RMD
HealthcareResMed Inc. · Medical - Devices · $30B
What is ResMed Inc.?
ResMed Inc. is a large-cap healthcare company specializing in medical devices and cloud-based software for sleep and respiratory care. Founded in 1995 and headquartered in San Diego, it serves both clinical and home-care markets globally.
ResMed generates revenue through two segments: Sleep and Respiratory Care, and Software as a Service. The device segment covers masks, ventilators, and diagnostic tools for conditions like sleep apnea. The SaaS segment provides cloud-based platforms — including Brightree and MatrixCare — that help out-of-hospital care providers manage patients and run their businesses.
ResMed was founded in 1995 and is headquartered in San Diego, California.
- CPAP and ventilation devices for sleep apnea and respiratory disorders
- AirView and myAir remote patient monitoring platforms
- Brightree business management software for home medical equipment providers
- MatrixCare care management solutions for senior living and home health
Is RMD a Good Stock to Buy?
UQS Score rates RMD as Very Good overall.
ResMed's strongest attributes are its Quality and Risk pillar ratings, both labeled Strong — reflecting consistent business fundamentals and a relatively resilient financial profile. Growth and Valuation both register as Good, suggesting the company is expanding at a reasonable pace without appearing excessively priced relative to its profile.
The Moat pillar is rated Neutral, indicating that competitive advantages, while present, are not yet assessed as dominant within the sector.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does RMD pay dividends?
Yes — ResMed Inc. pays a dividend.
ResMed pays a regular dividend, which is relatively uncommon among growth-oriented medical device companies. This reflects a business generating sufficient cash flow to reward shareholders while continuing to invest in product development and software expansion.
When does RMD report earnings?
ResMed reports earnings on a quarterly cadence, typical for US-listed equities.
The company's Quality and Growth pillar ratings suggest a track record of consistent revenue generation across both its device and SaaS segments. Demand for sleep and respiratory care solutions has remained durable across economic cycles.
For the most recent quarter's results, visit ResMed's investor relations page at resmed.com.
RMD Price History
+12.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in ResMed Inc.?
Based on ResMed Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does ResMed do?
ResMed develops medical devices and cloud-based software for sleep disorders and respiratory conditions. Its products range from CPAP masks and ventilators to SaaS platforms like Brightree and MatrixCare that help home-care and senior-living providers manage patients and operations.
Does RMD pay dividends?
Yes, ResMed pays a regular dividend. This is notable for a medical device company that also invests heavily in software and product development, suggesting the business generates reliable cash flow across its segments.
When does RMD report earnings?
ResMed reports on a quarterly cadence, consistent with US-listed large-cap equities. For confirmed dates and the latest results, check ResMed's official investor relations page.
Is RMD a good stock to buy?
UQS Score rates RMD as Very Good, with Strong marks on Quality and Risk. Whether it fits your portfolio depends on your goals and risk tolerance. The full pillar breakdown is available to Pro members on UQS Score.
Is RMD overvalued?
RMD's Valuation pillar is rated Good, suggesting the stock is not considered excessively priced relative to its quality and growth profile. Pro members can view the underlying metrics behind this assessment.
What is RMD's market cap bracket?
ResMed is classified as a large-cap stock, reflecting its scale as one of the leading medical device and healthcare software companies in the sleep and respiratory care space.
Who founded ResMed?
ResMed was founded by Peter Farrell, a biomedical engineer who built the company around research into sleep-disordered breathing. The company was established in 1995 and has since grown into a global healthcare technology leader.
Is RMD a long-term quality indicator?
RMD's Strong Quality and Risk pillar ratings suggest a business with durable fundamentals — a relevant signal for investors focused on long-term holding periods. The full analysis, including growth trajectory context, is available to Pro members.
Unlock Full RMD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare RMD against peers in the healthcare sector
- ✓Track score changes over time with Pro alerts
Pro Analysis
RMD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 73.7 | 90.2 | 52.0 | 62.1 | 100.0 | 71.7 | +0.2 |
| May 21, 2026 | 73.5 | 90.1 | 52.0 | 62.1 | 100.0 | 70.5 | -0.1 |
| May 19, 2026 | 73.6 | 90.2 | 52.0 | 62.1 | 100.0 | 70.8 | -0.4 |
| May 17, 2026 | 74.0 | 90.6 | 52.0 | 62.1 | 100.0 | 73.2 | +0.1 |
| May 16, 2026 | 73.9 | 90.6 | 52.0 | 62.1 | 100.0 | 72.0 | 0.0 |
| May 13, 2026 | 73.9 | 90.6 | 52.0 | 62.1 | 100.0 | 72.2 | +0.1 |
| May 12, 2026 | 73.8 | 90.5 | 52.0 | 62.1 | 100.0 | 71.8 | +0.3 |
| May 11, 2026 | 73.5 | 90.3 | 52.0 | 62.1 | 100.0 | 70.0 | -0.3 |
| May 7, 2026 | 73.8 | 89.9 | 52.0 | 62.0 | 100.0 | 72.6 | -0.2 |
| May 4, 2026 | 74.0 | 89.9 | 52.0 | 62.0 | 100.0 | 74.0 | +0.2 |
RMD — Pillar Breakdown
Quality
— 90.2/100 (25%)ResMed Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.1/100 (20%)ResMed Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 100.0/100 (15%)ResMed Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 70.8/100 (15%)ResMed Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 52/100 (25%)ResMed Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for RMD.
Score Composition
Financial Data
More Stock Analysis
How is the RMD UQS Score Calculated?
The UQS (Unified Quality Score) for ResMed Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses ResMed Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether ResMed Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.